Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RJx-03 + RJx-07
- Development stage
- Preclinical
- Lead developer
- Rejuvenate Biomed
- Administration
- Oral
01
Overview
RJx-03 + RJx-07 is a combination drug candidate currently in the discovery or preclinical stage of development by Rejuvenate Biomed. The candidate was identified using the company's proprietary drug discovery ecosystem, which includes CombinAge, an AI-enabled in silico platform for identifying synergistic drug combinations, and CelegAge, an in vivo platform utilizing *C. elegans* to screen for effects on healthspan and lifespan. While the specific therapeutic targets and indications for RJx-03 + RJx-07 remain undisclosed, the program aligns with Rejuvenate Biomed's mission to develop therapies that target the underlying mechanisms of aging to treat age-related diseases.
- Other names
- RJx-03/RJx-07
Beyond the preview
Go deeper on RJx-03 + RJx-07.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RJx-03 + RJx-07.